[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"endometrium-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:endometrium-cancer":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,62,96,123,156,175,197,226,250],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":34,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":58,"locationsCount":61},"100631678","phase-1-a-study-of-ide034-in-adult-participants-with-locally-advancedmetastatic-solid-tumors-types-100631678",false,"NCT07503808","A Study of IDE034 in Adult Participants With Locally Advanced\u002FMetastatic Solid Tumors Types","An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE034 in Adult Participants With Locally Advanced\u002FMetastatic Solid Tumors","Inclusion Criteria:\n\n1. Participant must be at least 18 years of age or the age of maturity per local regulations\n2. Participants with advanced recurrent or metastatic solid tumors expressing B7-H3 and PTK7 in the following indications: NSCLC, ESCC, endometrial cancer, HGSOC, HNSCC, TNBC (estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 \\[HER2\\] negative), CRC, and CRPC who have radiologically progressed or recurred on at least one line of therapy or is intolerant to additional effective standard therapies.\n3. Archival tissue sample for testing\n4. Measurable disease\n5. Have Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1.\n6. Have adequate bone marrow and organ function.\n7. Able to comply with contraceptive\u002Fbarrier requirements\n\nExclusion Criteria:\n\n1. Known symptomatic brain metastases or leptomeningeal metastasis\n2. Known primary CNS malignancy and any other malignancies within 2 years prior to the first dose.\n3. Have uncontrolled tumor-associated pain\n4. Have clinically significant cardiac abnormalities and\u002For cerebrovascular disease (stroke) within 6 months before the first dose\n5. Active uncontrolled infection\n6. Have history of interstitial pneumonitis, current noninfectious pneumonitis requiring steroid therapy; known or suspected interstitial pneumonitis as seen on screening imaging; other moderate to severe lung diseases seriously affecting respiratory function within 3 months before the first dose.\n7. Have history of severe infections within 4 weeks prior to the start of study treatment, including but not limited to bacteremia, severe pneumonia, or other serious infectious complications requiring hospitalization.\n8. Have history of immunodeficiency, with a positive human immunodeficiency virus (HIV) test at screening.\n9. Participants with known or suspected viral hepatitis\n10. Have history of active tuberculosis within 1 year before enrollment\n11. If participants had adverse reactions to previous antitumor treatment that have not recovered to guidelines of CTCAE Grade ≤ 1 and Grade 2 peripheral neurological symptoms\n12. Have received chemotherapy within 3 weeks of first dose of IMP; immunotherapy or biologic targeted antitumor treatments within 3 weeks before the first dose of IMP or other investigational products within 4 weeks of first dose of IMP\n13. Administration of any of the following\n\n    1. Current use or anticipated need for food or drugs that are known strong CYP3A4\u002F5 inhibitors or inducers\n    2. Have prior treatment with B7-H3 or PTK7 antibody-drug conjugate (ADC).\n    3. Have prior treatment with a topoisomerase I inhibitor (TOP1i), including an ADC with a TOP1i payload, within 6 months of first dose of IMP\n    4. Have received radiotherapy within 2 weeks prior to study entry\n    5. Have undergone major surgery or trauma within 4 weeks prior to study entry.\n    6. Have received live attenuated vaccine within 28 days prior to the first dose or are expected to receive live attenuated vaccine during the study treatment.\n    7. Female participants who are pregnant, lactating, or planning to become pregnant during the study period to 7 months after the last dose of IMP.\n    8. Are known to be allergic to any component or excipient of the IMP product or have a history of severe allergic reactions to other monoclonal antibody\u002Ffusion protein drugs.\n    9. Participants with complications in the eye including ulcers in the eye, and severe dry eye","ALL","18 Years",{"count":19,"type":20},150,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","This is a Phase 1a\u002F1b, open-label, multicenter dose escalation and dose expansion clinical study to evaluate the safety, PK, immunogenicity and preliminary efficacy of IDE034 in participants with locally advanced\u002Fmetastatic solid tumor types that express B7-H3 and PTK7.",[26,27,28,29,30,31,32,33],"Esophageal Squamous Cell Carcinoma","High Grade Serous Ovarian Cancer","Head and Neck Squamous Cell Carcinoma","Colorectal Cancer","Castration-resistant Prostate Cancer","Non Small Cell Lung Cancer","Endometrium Cancer","Triple Negative Breast Cancer",[26,35,36,28,37,38,39,29,40,30,41,42,43,44,45,46,47,48],"ESCC","Endometrial Cancer","HNSCC","Triple-negative Breast Cancer","TNBC","CRC","CRPC","Non-small Cell Lung Cancer","NSCLC","High-grade Serous Ovarian Cancer","HGSOC","Advanced, Metastic Solid Tumors","B7-H3 (CD276) and Protein Tyrosine Kinase 7 (PTK7)","IDE034","RECRUITING","2026-06-16",{"date":52,"type":53},"2026-06-18","ACTUAL",{"date":55,"type":53},"2026-02-24",{"date":57,"type":20},"2027-07-30",{"name":59,"class":60},"IDEAYA Biosciences","INDUSTRY",15,{"id":63,"slug":64,"hasResults":11,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":70,"minAge":17,"maxAge":4,"enrollmentInfo":71,"targetDuration":73,"studyType":74,"phases":4,"briefSummary":75,"conditions":76,"keywords":78,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":95},"100635915","the-surveillance-epidemiology-and-end-results-database-program-on-endometrial-cancer-in-the-italian-population-100635915","NCT07558889","The Surveillance, Epidemiology, and End Results Database Program on Endometrial Cancer in the Italian Population","The ENDOCancer-DATA: the Surveillance, Epidemiology, and End Results Database Program on Endometrial Cancer in the Italian Population","ENDOCancerDATA","Inclusion Criteria:\n\n* diagnosis of endometrial cancer (stage I-IV, G1-3, and special histotypes)\n* age \\> 18 years\n* American Society of Anesthesiologists classification (ASA score) 1-3\n* patients undergoing staging, cytoreduction or diagnostic surgery with acquisition of histological examination on which IHC and\u002For NGS studies have been performed for the molecular profile of the carcinoma\n* Signed informed consent\n\nExclusion Criteria:\n\n* patients with missing information\n* patients not treated in the participating centers for which only partial and fragmented information will be available\n* molecular profile not known and\\\\or not recoverable and retrospectively analysable","FEMALE",{"count":72,"type":20},10000,"10 Years","OBSERVATIONAL","The aim of this study is to lay the bases for an ambitious project that reports and records all the epidemiological-clinical information of the cases of endometrial carcinoma diagnosed and treated in the reference oncology centers involved on the national territory, to create a process of analysis of the data",[32,77],"Gynecologic Cancer",[79,80,81,82,83,84],"Molecular classification","Endometrial cancer treatment","Endometrial cancer epidemiology","Endometrial cancer surgical procedures","Minimally invasive surgery","Gynecologic Oncology","2026-04-27",{"date":87,"type":53},"2026-04-30",{"date":89,"type":53},"2024-04-01",{"date":91,"type":20},"2034-01-01",{"name":93,"class":94},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","OTHER",1,{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":70,"minAge":17,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":21,"phases":106,"briefSummary":108,"conditions":109,"keywords":110,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":95},"100617446","comparative-study-on-the-effect-of-diet-interventions-on-weight-loss-in-overweight-endometrial-cancer-patients-undergoing-fertility-sparing-treatment-100617446","NCT07318727","Comparative Study on the Effect of Diet Interventions on Weight Loss in Overweight Endometrial Cancer Patients Undergoing Fertility-sparing Treatment","Three-Way Diet Comparison for Weight Loss in Overweight Endometrial Cancer Patients on Fertility-Sparing Regimens: A Randomized Controlled Trial","Inclusion Criteria:\n\n* age ≥18 years old\n* diagnosed as endometrial cancer or atypical hyperplasia\n* fertility-preserving therapy\n* BMI≥25 kg\u002Fm2\n* informed consent.\n\nExclusion Criteria:\n\n* those with communication barriers\n* pregnant women\n* medical and surgical serious complications: urinary calculi, history of renal failure or severe renal insufficiency, familial dyslipidemia, severe liver disease, chronic metabolic acidosis, history of pancreatitis, severe diabetes mellitus, active gallbladder disease, fat dyspepsia, severe cardiovascular and cerebrovascular diseases.","40 Years",{"count":105,"type":20},81,[107],"NA","In this study, overweight and obese patients with endometrial cancer treated with fertility- sparing therapy were randomly divided into three groups. The first group was given Intermittent fasting, the second was given Low-energy balanced diet, the third group underwent routine care for self-weight management. Relevant information such as body morphology ,glycolipid metabolism and tumor outcomes of the subjects were collected. By evaluating the tumor outcome and changes in glycolipid metabolism indicators, to confirm the effectiveness and safety of diet interventions for overweight and obese patients with endometrial cancer and treatd with fertility preservation.",[32],[111,112,113],"Endometrial Neoplasms","Dietary Patterns","Body Weight","2026-01-04",{"date":116,"type":53},"2026-01-06",{"date":118,"type":53},"2025-01-10",{"date":120,"type":20},"2026-03-31",{"name":122,"class":94},"Peking University People's Hospital",{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":130,"targetDuration":4,"studyType":21,"phases":132,"briefSummary":134,"conditions":135,"keywords":143,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":155},"100508635","phase-1-a-phase-iii-study-of-vls-1488-in-subjects-with-advanced-cancer-100508635","NCT05902988","A Phase I\u002FII Study of VLS-1488 in Subjects With Advanced Cancer","A Phase I\u002FII Study of VLS-1488 (an Oral KIF18A Inhibitor) in Subjects With Advanced Cancer","Key Inclusion Criteria:\n\n* All Parts: Age ≥ 18 years, ECOG Performance Status ≤ 1, at least 1 site of measurable disease evaluable by CT scan or MRI per RECIST 1.1, able to take oral medication without alteration\n* Dose Escalation: No available therapeutic options to provide clinically meaningful benefits in the following tumor types: High Grade Serous Ovarian Cancer, Squamous Non -Small Cell Lung Cancer, Triple Negative Breast Cancer, Gastric Adenocarcinoma (not EBV+), Colorectal, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction, Bladder (transitional cell), Head and Neck Squamous Cell Carcinomas (not nasopharynx, sinonasal or lip), Ovarian Carcinosarcoma, CN-high Endometrial\u002FUterine\n* Dose Expansion: Must have been previously treated with several lines of standard of care treatment specified in the protocol in the following tumor types: High Grade Serous Ovarian Cancer, Squamous Non-Small Cell Lung Cancer, Triple Negative Breast Cancer, Gastric Adenocarcinoma (not EBV+), Colorectal, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Head and Neck Squamous Cell Carcinomas (not nasopharynx, sinonasal or lip), CN-high Endometrial\u002FUterine\n\nKey Exclusion Criteria:\n\n* MSI-H, dMMR, POLE gene hotspot mutated, or known hypermutator phenotype\n* Previously received KIF18A inhibitor\n* Current CNS metastases or leptomeningeal disease\n* Cardiac parameters: MI or stroke ≤ 1 year, unstable angina\u002FPE\u002FDVT\u002FCABG ≤ 6 months, NYHA Class ≥ II, LVEF \\\u003C 50%\n* Inability to comply with concomitant medication restrictions with respect to strong inhibitors and inducers of CYP3A, and clinical inhibitors of MDR1 (P-gp) and BCRP\n* Any clinically significant ascites or pleural effusions at time of enrollment, or any therapeutic paracentesis or thoracentesis within 28 days of planned first dose of study drug\n* Bowel obstruction or GI perforation within 6 months of planned first dose of study drug",{"count":131,"type":20},200,[23,133],"PHASE2","This is a first-in-human phase I\u002FII study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers.",[136,137,138,33,28,139,140,141,32,142],"Advanced Solid Tumor","High Grade Serous Adenocarcinoma of Ovary","Squamous Non-small-cell Lung Cancer","Ovarian Carcinosarcoma","Uterine Carcinosarcoma","Uterine Serous Carcinoma","Chromosomal Instability",[144,45,39,37,145],"KIF18A Inhibitor","sqNSCLC","2025-10-31",{"date":148,"type":53},"2025-11-04",{"date":150,"type":53},"2023-10-18",{"date":152,"type":20},"2026-12",{"name":154,"class":60},"Volastra Therapeutics, Inc.",14,{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":160,"acronym":4,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":70,"minAge":17,"maxAge":4,"enrollmentInfo":162,"targetDuration":4,"studyType":21,"phases":164,"briefSummary":165,"conditions":166,"keywords":4,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":95},"100529105","weight-management-in-overweight-endometrial-cancer-patients-undergoing-fertility-sparing-treatment-100529105","NCT06169449","Weight Management in Overweight Endometrial Cancer Patients Undergoing Fertility-sparing Treatment","Inclusion Criteria:\n\n* age ≥18 years old\n* diagnosed as endometrial cancer or atypical hyperplasia\n* immunohistochemical staining and sequencing of pathological tissue\n* fertility-preserving therapy\n* BMI≥25 kg\u002Fm2\n* informed consent.\n\nExclusion Criteria:\n\n* those with communication barriers\n* pregnant women\n* medical and surgical serious complications: urinary calculi, history of renal failure or severe renal insufficiency, familial dyslipidemia, severe liver disease, chronic metabolic acidosis, history of pancreatitis, severe diabetes mellitus, active gallbladder disease, fat dyspepsia, severe cardiovascular and cerebrovascular diseases.",{"count":163,"type":20},240,[107],"In this study, overweight and obese patients with endometrial cancer treated with fertility- sparing therapy were randomly divided into two groups. The test group was given weight management, while the control group was given routine care. Relevant information such as body morphology and composition, glycolipid metabolism, molecular typing and tumor outcomes of the subjects were collected. By evaluating the tumor outcome and changes in glycolipid metabolism indicators, to confirm the effectiveness and safety of weight management for overweight and obese patients with endometrial cancer and treatd with fertility preservation.",[32],"2025-08-31",{"date":169,"type":53},"2025-09-03",{"date":171,"type":53},"2022-04-01",{"date":173,"type":20},"2026-12-31",{"name":122,"class":94},{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":70,"minAge":17,"maxAge":4,"enrollmentInfo":182,"targetDuration":4,"studyType":74,"phases":4,"briefSummary":184,"conditions":185,"keywords":186,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":95},"100580772","ai-and-machine-learning-based-risk-prediction-model-to-improve-the-clinical-management-of-endometrial-cancer-100580772","NCT06841653","A.I and Machine Learning Based Risk Prediction Model to Improve the Clinical Management of Endometrial Cancer.","A.I and Machine Learning Based Risk Prediction Model to Improve the Clinical Management of Endometrial Cancer: a Composite Approach Integrating the MultiOMics IMmune-IConographic Pattern (MOMIMIC Score) Towards Precision Oncology and Surgery.","Inclusion Criteria:\n\n* Age \\> 18 years;\n* Histological diagnosis of endometrial hyperplasia, endometrioid adenocarcinoma of the endometrium, healthy endometrium in patients undergoing total hysterectomy for benign extra-endometrial disease;\n* Written informed consent (to the study and data processing), for the party's patients only prospective and\u002For in follow-up) For the retrospective cohort: availability of samples adequately stored at the biobank of the Institute and availability of data relating to follow-up (at least 2 years)\n\nExclusion Criteria:\n\nAll exclusion criteria adopted in the surgical protocols will be applied to the study. In particular:\n\n* Comorbidities not controlled with adequate medical therapy;\n* Infections of the endometrial cavity (pyometra);\n* Synchronous cancer;\n* Neoadjuvant treatments;\n* Previous radiotherapy treatments of the pelvic region;\n* Hormone therapies.",{"count":183,"type":20},40,"Prediction of preoperative endometrial biopsy: the evolution from hyperplasia to cancer, the prognosis and the risk of recurrence. Intelligence methods artificial risk will be used to redefine the current risk classes including our profile immuno-mutational to provide a more precise characterization and closer to the real prognosis of the patient.",[32],[187],"MultiOMics IMmune-IConographic pattern","2025-02-18",{"date":190,"type":53},"2025-02-24",{"date":192,"type":53},"2024-06-20",{"date":194,"type":20},"2026-06-20",{"name":196,"class":94},"Regina Elena Cancer Institute",{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":4,"eligibilityCriteria":203,"healthyVolunteers":11,"sex":70,"minAge":4,"maxAge":4,"enrollmentInfo":204,"targetDuration":4,"studyType":21,"phases":206,"briefSummary":207,"conditions":208,"keywords":211,"overallStatus":216,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":95},"100576124","effect-of-motivational-interviewing-on-posttraumatic-stress-symptoms-and-posttraumatic-growth-in-women-with-endometrial-cancer-100576124","NCT06781216","Effect of Motivational Interviewing on Posttraumatic Stress Symptoms and Posttraumatic Growth in Women with Endometrial Cancer","Effect of Motivational Interviewing on Posttraumatic Stress Symptoms and Posttraumatic Growth in Women with Endometrial Cancer: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Must be a native Turkish speaker and have no communication barriers\n* Have been diagnosed with endometrial cancer\n* Not be in the process of active treatment (chemotherapy, radiotherapy, hormone therapy, etc.)\n* Be willing to participate in the study\n* Have digital literacy.\n\nExclusion Criteria:\n\n* Not having mental capacity\u002FHaving a psychotic disorder\n* Being in the process of active treatment (chemotherapy, radiotherapy, hormone therapy, etc.)",{"count":205,"type":20},66,[107],"Cancer is still the second leading cause of death worldwide with approximately 9.6 million deaths per year. Gynecological cancers, which are the most common type of cancer among women, significantly affect the quality of life by disrupting the functions of the reproductive system of women. Endometrial cancer has an important place due to its prevalence in our country and worldwide. Although stress factors related to endometrial cancer may continue after the completion of treatment, this situation has the potential to negatively affect the psychological and physiological health of women. This research is a randomized controlled trial aiming to evaluate the effect of motivational interviewing applied to women who completed endometrial cancer treatment and were followed up in the outpatient clinic on post-traumatic stress symptoms and post-traumatic growth. Simple randomization method will be used in the study. The sample size to be included in the study was determined as 66 participants in total, 33 in the intervention group and 33 in the control group. In the study, the effectiveness of motivational interviewing technique application in women with endometrial cancer will be evaluated based on evidence using Post-Traumatic Stress Disorder Checklist for DSM-5, Post-Traumatic Growth Scale and Ways of Coping Scale. Research data will be collected from women who meet the inclusion criteria at Akdeniz University Hospital Gynecology and Obstetrics Clinic between January 2 and August 31, 2025. The motivational interviews planned to be implemented as an intervention method in the research aim to reduce post-traumatic stress symptoms, develop coping strategies and increase the level of post-traumatic growth in women with endometrial cancer.",[32,209,210],"Post Traumatic Stress Symptoms","Post Traumatic Growth, Psychological",[212,213,214,215],"Endometrium cancer","Motivational interviewing","Post traumatic growth","Post traumatic stress symptoms","NOT_YET_RECRUITING","2025-01-13",{"date":219,"type":53},"2025-01-17",{"date":221,"type":20},"2025-02-03",{"date":223,"type":20},"2025-12-31",{"name":225,"class":94},"Akdeniz University",{"id":227,"slug":228,"hasResults":11,"nctId":229,"briefTitle":230,"officialTitle":230,"acronym":4,"eligibilityCriteria":231,"healthyVolunteers":11,"sex":70,"minAge":17,"maxAge":4,"enrollmentInfo":232,"targetDuration":4,"studyType":74,"phases":4,"briefSummary":234,"conditions":235,"keywords":236,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":95},"100378850","stratifying-endometrial-cancer-patients-using-a-petmri-prognostic-model-100378850","NCT04212910","Stratifying Endometrial Cancer Patients Using a PET\u002FMRI Prognostic Model","Inclusion Criteria:\n\n* histopathological confirmation of a primary endometrial cancer\n* age \\> 18 years\n* no contraindication to surgery (comorbidity, contraindication or lack of consent)\n* no contraindication to preoperative imaging\n* visible tumor at imaging\n* signed inform consent.\n\nExclusion Criteria:\n\n* patients unsuitable for surgical intervention (comorbidity, contraindication or lack of consent, poor performance status)\n* age \\\u003C 18 years, c) inability to complete the needed imaging examination (ie, severe claustrophobia)\n* any additional medical condition that may significantly interfere with study compliance\n* all the contraindication for MRI (ie, pacemaker).",{"count":233,"type":20},101,"Endometrial cancer (EC) is the most common gynecological malignancy in high-income countries. Prognosis and treatment are dictated by cancer histological subtype and grade coupled with surgical staging as described by Surgical International Federation of Gynecology and Obstetrics (FIGO) staging system. Surgery is the elective standard treatment and used for staging of EC. The purpose of this study is to collect images from a simultaneous PET\u002FMRI study from which to extrapolate a preoperative, non-invasive, prognostic model.",[32],[237,238,239,240],"endometrium","cancer","PET-MRI","stratification","2024-04-11",{"date":243,"type":53},"2024-04-12",{"date":245,"type":53},"2019-07-23",{"date":247,"type":20},"2027-02-28",{"name":249,"class":94},"IRCCS San Raffaele",{"id":251,"slug":252,"hasResults":11,"nctId":253,"briefTitle":254,"officialTitle":255,"acronym":256,"eligibilityCriteria":257,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":258,"targetDuration":4,"studyType":21,"phases":260,"briefSummary":261,"conditions":262,"keywords":263,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":269,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":275,"locationsCount":95},"100363616","phase-1-pembrolizumab-with-ataluren-in-patients-with-metastatic-pmmr-and-dmmr-colorectal-carcinoma-or-metastatic-dmmr-endometrial-carcinoma-the-atapembro-study-100363616","NCT04014530","Pembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorectal Carcinoma or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO Study","Study of Pembrolizumab Combined With Ataluren In Patients With Metastatic pMMR and dMMR Colorectal Adenocarcinomas or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO Study","ATAPEMBRO","In order to be eligible for participation in this trial, the subject must:\n\n* Have at least one lesion with measurable disease as defined by 10mm in longest diameter for a soft tissue lesions or 15mm in short axis for a lymph node by RECIST 1.1 and irRC criteria for response assessment.\n* Have received at least 1 prior cancer therapy regimen for metastatic CRC, or have refused palliative chemotherapy. In the latter case this should have been documented.\n* Have a life expectancy of greater than 3 months.\n* Have normal organ and marrow function as defined in protocol\n* Be willing and able to provide written informed consent\u002Fassent for the trial.\n* Be at least 18 years of age on day of signing informed consent.\n* Be willing to provide tissue from a newly obtained pre-treatment core or excisional biopsy of a metastatic tumor lesion and the primary tumor lesion (when in place). Subjects for whom newly-obtained samples cannot be provided (e.g. inaccessible by colonoscopy or CT-guided approaches or due to safety concerns) may submit an archived specimen only upon agreement from the Sponsor.\n* Be willing to provide tissue post-treatment of a core or excisional biopsy of a metastatic tumor lesion (when still in place) or of the primary tumor (when in place).\n* Have a performance status of 0 or 1 on the ECOG Performance Scale.\n* Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.\n* Male subjects of childbearing potential (Section 4.7.2) must agree to use an adequate method of contraception as outlined in Section 4.7.2- Contraception, starting with the first dose of study therapy through 120 days after the last dose of study therapy.\n\nSubject must be excluded from participating in the trial if the subject:\n\n* Has known active central nervous system (CNS) metastases and\u002For carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 1 week prior to trial treatment.\n* Has a history of prior treatment with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, anti-OX-40, anti-CD40, or anti-CTLA-4 antibodies.\n* Has received growth factors including, but not limited to, granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (GM-CSF), erythropoietin, etc. within 2 weeks of study drug administration. Use of such agents while on study is also prohibited. Prior use of growth factors should be documented in the patient's medical history.\n* Has an uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* Has a history of any autoimmune disease: Patients with a history of inflammatory bowel disease, including ulcerative colitis and Crohn's Disease, are excluded from this study, as are patients with a history of symptomatic disease (e.g., rheumatoid arthritis, systemic progressive sclerosis \\[scleroderma\\], systemic lupus erythematosus, autoimmune vasculitis \\[e.g., Wegener's Granulomatosis\\]); CNS or motor neuropathy considered of autoimmune origin (e.g., Guillain-Barre Syndrome and Myasthenia Gravis, multiple sclerosis). Patients with thyroid disease will be allowed. Autoimmune diagnoses not listed here must be approved by the protocol chair.\n* Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.\n* Has a known history of active TB (Bacillus Tuberculosis)\n* Hypersensitivity to pembrolizumab or ataluren or any of their excipients.\n* Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier.\n* Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent.\n* Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.\n* Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.\n* Has known history of, or any evidence of active, non-infectious pneumonitis.\n* Has an active infection requiring systemic therapy.\n* Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.\n* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n* Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment.\n* Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1\u002F2 antibodies).\n* Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA \\[qualitative\\] is detected).\n* Has received a live vaccine within 30 days of planned start of study therapy.\n* Has received amino glucoside antibiotics within 3 days of planned start of study therapy",{"count":259,"type":20},47,[23,133],"Single Center, open label, Phase I-II trial designed to test the safety and efficacy of the combination of Ataluren and Pembrolizumab for the treatment of metastatic mismatch repair deficient and proficient colorectal adenocarcinoma and metastatic mismatch repair deficient endometrial carcinoma.",[29,32],[264,265,266,267],"Mismatch repair","Anti PD1","Immunotherapy","Metastatic disease","2023-01-31",{"date":270,"type":53},"2023-02-01",{"date":272,"type":53},"2019-08-01",{"date":274,"type":20},"2023-08-01",{"name":276,"class":94},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)"]